Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Average Recommendation of “Hold” by Brokerages

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) has received a consensus recommendation of “Hold” from the eight brokerages that are covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $34.3333.

A number of analysts have commented on the company. Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings cut Lakefront Biotherapeutics American Depositary Shares from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley initiated coverage on Lakefront Biotherapeutics American Depositary Shares in a report on Friday, July 10th. They set an “equal weight” rating and a $30.00 price target for the company.

Lakefront Biotherapeutics American Depositary Shares Stock Down 0.3%

Shares of LKFT stock opened at $26.91 on Tuesday. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -19.09 and a beta of 0.27. Lakefront Biotherapeutics American Depositary Shares has a 52 week low of $25.68 and a 52 week high of $37.78. The firm has a 50 day moving average of $28.65 and a 200-day moving average of $30.11.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its earnings results on Monday, August 10th. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.97) by $1.01. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $7.29 million. Analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several large investors have recently made changes to their positions in LKFT. State of Wyoming purchased a new stake in Lakefront Biotherapeutics American Depositary Shares during the second quarter worth about $28,000. Van ECK Associates Corp boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 61.6% in the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares during the last quarter. Arax Advisory Partners grew its position in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% during the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,778 shares during the period. Quadrant Capital Group LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at approximately $134,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter worth approximately $211,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.